| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.gennexlab.com | |
| Market Cap | 303.24 Cr. | |
| Enterprise Value(EV) | 325.11 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 0.45 | Trailing Twelve Months Ending 2023-09 |
| Price-Earning Ratio (PE) | 37.95 | Trailing Twelve Months Ending 2023-09 |
| Industry PE | 38.54 | Trailing Twelve Months Ending 2023-09 |
| Book Value / Share | 4.72 | Trailing Twelve Months Ending 2023-09 |
| Price to Book Value | 3.59 | Calculated using Price: 16.94 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 17.90 Cr. | 179,009,534 Shares |
| FaceValue | 1 | |
| About Gennex Laboratories Ltd. | ||
| Gennex Laboratories (formerly Prudential Pharmaceuticals) is a public limited company established in the year 1995 and has been engaged in the manufacturing of bulk drugs and intermediates. The company started as one of the leading manufacturer and exporter of bulk drugs and intermediates. Quality is the strength of the company and major part of its finished products are exported to various countries viz. Germany, United Kingdom, Spain, Singapore, Canada, Switzerland, Iran, Bangladesh, Pakistan and other major countries. Gennex Laboratories has diversified its activities to biotech products in order to have better prospects and opportunities for the company for expanding its bussiness activities and to meet the marketing requirements. | ||
| 1 Day |
|
-0.35% |
| 1 Week |
|
+5.41% |
| 1 Month |
|
+40.23% |
| 3 Month |
|
+111.75% |
| 6 Month |
|
+139.94% |
| 1 Year |
|
+180.93% |
| 2 Year |
|
+119.71% |
| 5 Year |
|
+369.25% |
| 10 Year |
|
+2252.78% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 2.57 | 8.69 | 9.14 | 2.67 | 6.75 | 5.32 | 10.66 | 9.35 | 7.43 | |
| Return on Capital Employed (%) | 4.57 | 11.78 | 11.61 | 6.31 | 10.49 | 8.32 | 13.18 | 11.78 | 10.70 | |
| Return on Assets (%) | 1.66 | 5.77 | 5.94 | 1.68 | 4.34 | 3.40 | 6.95 | 6.16 | 5.55 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 26 | 28 | 31 | 32 | 34 | 36 | 40 | 44 | 79 | 85 | |
| Non Curr. Liab. | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 2 | ||
| Curr. Liab. | 13 | 12 | 17 | 18 | 17 | 21 | 19 | 24 | 16 | 18 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 39 | 42 | 49 | 50 | 52 | 57 | 59 | 68 | 96 | 104 | |
| Non Curr. Assets | 22 | 23 | 23 | 23 | 23 | 22 | 23 | 21 | 24 | 24 | |
| Curr. Assets | 17 | 19 | 26 | 28 | 29 | 35 | 36 | 47 | 72 | 81 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 39 | 42 | 49 | 50 | 52 | 57 | 59 | 68 | 96 | 104 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09 Rs. Cr. TTM |
| Net Sales | 32 | 39 | 42 | 44 | 56 | 56 | 60 | 61 | 65 | 61 | |
| Other Income | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 3 | 2 | |
| Total Income | 32 | 39 | 42 | 45 | 57 | 57 | 60 | 63 | 69 | 63 | |
| Total Expenditure | -30 | -34 | -37 | -42 | -52 | -52 | -53 | -56 | -61 | -50 | |
| PBIDT | 2 | 4 | 5 | 3 | 5 | 4 | 7 | 7 | 8 | 13 | |
| Interest | 0 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Taxation | 0 | -1 | 0 | -1 | -1 | -1 | -1 | -1 | -1 | -3 | |
| Exceptional Items | 0 | 0 | 0 | 0 | |||||||
| PAT | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 4 | 5 | 8 | |
| Adjusted EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | 0 | 3 | 0 | 3 | 2 | -2 | -1 | 7 | -14 | |
| Cash Fr. Inv. | -1 | 0 | -1 | -1 | -1 | -1 | 0 | 0 | -1 | -1 | |
| Cash Fr. Finan. | 0 | 0 | -2 | 1 | -2 | 1 | 0 | 2 | 2 | 21 | |
| Net Change | 0 | 0 | 0 | 0 | 0 | 2 | -2 | 0 | 7 | 6 | |
| Cash & Cash Eqvt | 0 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 8 | 14 |
|
Mon, 04 Dec 2023
EGM Of Gennex Laboratories Limited - BSE Script Code: 531739 Pursuant to Regulation 42 of SEBI (LODR) Regulations 2015 the Register of Members and Share Transfer Books of the Company will remain closed from 24.12.2023 to 30.12.2023 (both days inclusive) for the purpose of EGM to be held on Saturday 30.12.2023 to seek the approval of the shareholders of the Company inter alia in relation to:1. Increase in authorised share capital from Rs. 20 Crore to 25 Crore.2. Issuance of upto 5 00 00 000 equity shares of the Company having face value of Re.1/- each on preferential basis to specified persons.3. Issuance of upto 1 55 00 000 share warrants of the Company to the promoters and members of the promoter group on a preferential basis.The intimation is also being uploaded on the Company website: www.gennexlab.comWe request you to take the above information on record and acknowledge the receipt of the same. |
|
Mon, 04 Dec 2023
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for JMS Mining Pvt Ltd |
|
Sat, 02 Dec 2023
Board Meeting Outcome for Outcome Of The Board Meeting Held On December 02 2023 Pursuant to the provisions of Regulation 30 of the SEBI (LODR) Regulations 2015 in furtherance to our intimation dated 20/11/2023 and 29/11/2023 we wish to inform you that Board of Directors of the Company at its meeting held today on 02/12/2023 has considered and approved the following:1. To increase the authorised share capital of the Company from Rs. 20 Crore to Rs. 25 Crore and consequential alteration in Clause V of the MOA and Clause 4(i) of the AOA of the Company subject to approval of the shareholders of the Company.2. Issuance of upto 5 00 00 000 equity shares of the Company having face value of Rs. 1/- each on preferential basis to specified persons3. Issuance of upto 1 55 00 000 share warrants of the Company to the promoters and members of promoter group on a preferential basis4. Calling of Extraordinary General Meeting5. Book Closure for ensuing EGM and record date/ cut-off date for e-voting.The meeting commenced at 2:00 pm and concluded at 4:00 pm. |
| Fri, 08 Dec 2023 |
Opening at High
|
Closing Below Previous Low
|
Close Within 52 Week High Zone
|
Close Above Last Week High
|
Close Above Last Month High
|
Equities
M.F.
Sectors
StockEdge Social